AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) will announce its second-quarter 2026 earnings on Friday, July 31, 2026, before the market opens. The company will host a live earnings conference call webcast at 8 a.m. Central time, accessible via its investor relations website, with an archived replay available later that day.
BOTOX Cosmetic (NYSE: ABBV), from Allergan Aesthetics, introduced the 2026 cohort of The Confidence Collective: Empowering Women Entrepreneurs, selecting 250 women for a multi-week skill-building, mentorship, and networking program.
Twenty participants will each receive a $20,000 grant to support their business goals, with recipients to be announced in fall 2026.
Allergan Aesthetics (NYSE: ABBV) received Health Canada approval for Boey® (trenibotulinumtoxinE) to temporarily improve moderate to severe glabellar (frown) lines in adults.
Boey is the first approved serotype E aesthetic neurotoxin, offering rapid onset with results from about eight hours and a short duration of roughly two to three weeks.
AbbVie (NYSE: ABBV) received European Commission approval for MAVIRET (glecaprevir/pibrentasvir) to treat acute hepatitis C virus (HCV) infection with compensated liver disease, with or without cirrhosis, in adults and children aged 3+ years.
MAVIRET is now the only treatment approved in the EU for both acute and chronic HCV infection. Approval is supported by a Phase 3 study of an eight-week regimen, which showed high efficacy and mainly mild to moderate adverse events such as fatigue, diarrhea, headache and asthenia.
AbbVie (NYSE: ABBV) received European Commission approval for SKYRIZI (risankizumab) to treat children and adolescents aged six years and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.
The decision is backed by Phase 3 OptIMMize-1 and OptIMMize-2 data and introduces a 55 mg pre-filled syringe for patients under 40 kg, with pediatric safety (n=137) consistent with adults and no new safety signals reported.
AbbVie (NYSE: ABBV) agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal adds late-stage immunology assets, including lead antibody zumilokibart (APG777) for atopic dermatitis and APG273 for asthma, and is expected to close in Q3 2026 and be accretive to adjusted diluted EPS beginning in 2032.
AbbVie (NYSE: ABBV) announced its board declared a quarterly cash dividend of $1.73 per share. The dividend is payable August 14, 2026, to shareholders of record on July 15, 2026. Since 2013, AbbVie has raised its dividend by over 330% and is part of the S&P Dividend Aristocrats Index.
Allergan Aesthetics (NYSE: ABBV) received U.S. FDA approval for SKINVIVE by JUVÉDERM to improve neck appearance by reducing horizontal neck lines in adults over 21. This is its second indication after cheek skin smoothness.
SKINVIVE is the first and only FDA-approved hyaluronic acid injectable for neck lines, showing six-month results with optimal treatment and a mostly mild, transient safety profile.
AbbVie (NYSE: ABBV) reported nine-year Phase 3 CLL14 results for fixed-duration VENCLEXTA/VENCLYXTO (venetoclax) plus obinutuzumab in previously untreated chronic lymphocytic leukemia at EHA 2026.
The regimen showed median progression-free survival of 6.4 vs 3.2 years and median time to next treatment of 7.6 years, after one year of therapy.
Allergan Aesthetics (NYSE:ABBV) released “What Consumers Really Want”, the latest report in The Aesthetics Evolution series, profiling today’s aesthetics consumers and their expectations from personalized, end-to-end aesthetic experiences.
The report highlights themes on spending priorities, desire for natural results, value of in-depth consultations, trust in providers, and proactive approaches to aging.